Developing Novel Treatments to Combat Severe Hypertriglyceridemia
Hypertriglyceridemia is a common condition characterized by high levels of triglycerides, a type of fat, in the bloodstream.1 Individuals with severe hypertriglyceridemia (SHTG) have triglyceride levels more than three times the normal level.2 SHTG can lead to multiple serious conditions, including cardiovascular disease (CVD) and acute pancreatitis.1 Pfizer aims to help address SHTG through the development of novel medicines aimed at lowering levels of triglycerides to minimize the impact of this serious condition.
View more information about our pipeline below.
- Read SHTG-related feature stories
- Learn SHTG basics
- See more information about our pipeline and Pfizer clinical trials